少点错误 2024年07月12日
Superbabies: Putting The Pieces Together
index_new5.html
../../../zaker_core/zaker_tpl_static/wap/tpl_guoji1.html

 

本文探讨了“设计婴儿”的可行性,分析了利用基因筛选和迭代胚胎选择技术创造具有特定遗传特征的婴儿的可能性。文章首先介绍了多基因评分的概念,并解释了其在预测特定性状和疾病风险方面的应用。接着,文章讨论了基因编辑技术的局限性,指出目前基因编辑技术无法实现对整个身体的多基因编辑,且存在潜在的脱靶效应。最后,文章重点介绍了迭代胚胎选择和迭代减数分裂两种技术,并分析了它们的优缺点。

🤔 **多基因评分:预测性状和疾病风险的关键** 多基因评分是一种利用统计学方法,根据个体基因组信息预测其特定性状或疾病风险的方法。它通过分析大量基因与性状或疾病之间的关联,建立统计模型,并根据个体基因型预测其性状或疾病的可能性。多基因评分在预测一些复杂性状,例如身高、智力、癌症风险等方面具有应用价值,但其预测精度仍需进一步提高。 例如,多基因评分可以用于预测个体患某些疾病的风险,如癌症、心脏病等。通过对个体的基因组进行分析,可以确定其携带的与这些疾病相关的基因变异,并根据这些变异预测其患病风险。 多基因评分还可以用于预测一些复杂性状,例如身高、智力等。这些性状受多个基因共同控制,无法通过单个基因的变异来准确预测。多基因评分通过分析多个基因与这些性状之间的关联,建立统计模型,可以更准确地预测个体的身高、智力等性状。

🧬 **基因编辑技术的局限性:挑战重重** 虽然基因编辑技术近年来取得了重大进展,但目前仍无法实现对整个身体的多基因编辑。现有的基因编辑技术主要针对血液等易于获取的细胞进行编辑,而对大脑等难以到达的器官的基因编辑技术尚未成熟。此外,基因编辑技术还存在潜在的脱靶效应,即编辑目标基因的同时,也可能意外地改变了其他基因,从而导致不可预测的后果。 例如,目前已批准的基因编辑疗法主要集中在血液疾病的治疗,如镰状细胞病。这些疗法通过对患者的血液细胞进行基因编辑,使其能够产生正常的血红蛋白,从而缓解疾病症状。然而,这些疗法无法对其他器官的基因进行编辑,也无法解决与多个基因相关的复杂疾病。 基因编辑技术还存在脱靶效应的风险。基因编辑工具可能无法完全精准地定位到目标基因,可能会错误地编辑其他基因,导致不可预测的后果。因此,在应用基因编辑技术时,需要谨慎评估其安全性,并进行严格的临床试验。

🧪 **迭代胚胎选择:逐代筛选,优化性状** 迭代胚胎选择是一种通过多轮筛选,选择具有较高多基因评分的胚胎,并将其培养成新的胚胎,从而逐代提高特定性状的效率。这种方法类似于传统的育种技术,通过不断选择具有优良性状的个体进行交配,从而获得具有更好性状的后代。 迭代胚胎选择的主要优势在于,它不需要进行基因编辑,可以避免基因编辑带来的潜在风险。此外,它可以利用现有的多基因评分技术,筛选具有较高评分的胚胎,从而提高特定性状的效率。 然而,迭代胚胎选择也存在一些局限性。首先,它需要进行多轮筛选,时间成本较高。其次,它需要对胚胎进行多次培养,可能会影响胚胎的发育。最后,它也存在伦理方面的争议,例如是否应该对胚胎进行选择,以及如何确保选择过程的公平性。

🧫 **迭代减数分裂:更快捷高效的基因筛选** 迭代减数分裂是一种利用减数分裂过程,对细胞进行基因筛选,并通过融合筛选后的细胞,获得具有更高评分的个体的技术。该技术通过诱导体细胞进行减数分裂,生成多个单倍体细胞,然后对这些细胞进行基因型分析,选择具有较高评分的细胞进行融合,生成新的二倍体细胞。 迭代减数分裂技术相比迭代胚胎选择,具有更快的速度和更高的效率。它不需要进行胚胎培养,也不需要进行多次筛选,可以有效地减少时间成本。此外,它可以利用现有的减数分裂诱导技术,以及基因型分析技术,实现高效的基因筛选。 然而,迭代减数分裂技术也存在一些挑战。目前,诱导体细胞进行减数分裂的技术还处于研究阶段,需要进一步完善。此外,该技术也存在伦理方面的争议,例如是否应该对细胞进行筛选,以及如何确保筛选过程的公平性。

Published on July 11, 2024 8:40 PM GMT

This post was inspired by some talks at the recent LessOnline conference including one by LessWrong user “Gene Smith”.

Let’s say you want to have a “designer baby”. Genetically extraordinary in some way — super athletic, super beautiful, whatever.

6’5”, blue eyes, with a trust fund.

Ethics aside1, what would be necessary to actually do this?

Fundamentally, any kind of “superbaby” or “designer baby” project depends on two steps:

1.) figure out what genes you ideally want;

2.) create an embryo with those genes.

It’s already standard to do a very simple version of this two-step process. In the typical course of in-vitro fertilization (IVF), embryos are usually screened for chromosomal abnormalities that would cause disabilities like Down Syndrome, and only the “healthy” embryos are implanted.

But most (partially) heritable traits and disease risks are not as easy to predict.

Polygenic Scores

If what you care about is something like “low cancer risk” or “exceptional athletic ability”, it won’t be down to a single chromosomal abnormality or a variant in a single gene. Instead, there’s typically a statistical relationship where many genes are separately associated with increased or decreased expected value for the trait.

This statistical relationship can be written as a polygenic score — given an individual’s genome, it’ll crunch the numbers and spit out an expected score. That could be a disease risk probability, or it could be an expected value for a trait like “height” or “neuroticism.”

Polygenic scores are never perfect — some people will be taller than the score’s prediction, some shorter — but for a lot of traits they’re undeniably meaningful, i.e. there will be a much greater-than-chance correlation between the polygenic score and the true trait measurement.

Where do polygenic scores come from?

Typically, from genome-wide association studies, or GWAS. These collect a lot of people’s genomes (the largest ones can have hundreds of thousands of subjects) and personal data potentially including disease diagnoses, height and weight, psychometric test results, etc. And then they basically run multivariate correlations. A polygenic score is a (usually regularized) multivariate regression best-fit model of the trait as a function of the genome.

A polygenic score can give you a rank ordering of genomes, from “best” to “worst” predicted score; it can also give you a “wish list” of gene variants predicted to give a very high combined score.

Ideally, “use a polygenic score to pick or generate very high-scoring embryos” would result in babies that have the desired traits to an extraordinary degree. In reality, this depends on how “good” the polygenic scores are — to what extent they’re based on causal vs. confounded effects, how much of observed variance they explain, and so on. Reasonable experts seem to disagree on this.2

I’m a little out of my depth when it comes to assessing the statistical methodology of GWAS studies, so I’m interested in another question — even assuming you have polygenic score you trust, what do you do next? How do you get a high-scoring baby out of it?

Massively Multiplexed, Body-Wide Gene Editing? Not So Much, Yet.

“Get an IVF embryo and gene-edit it to have the desired genes” (again, ethics and legality aside)3 is a lot harder than it sounds.

First of all, we don’t currently know how to make gene edits simultaneously and abundantly in every tissue of the body.

Recently approved gene-editing therapies like Casgevy, which treats sickle-cell disease, are operating on easy mode. Sickle-cell disease is a blood disorder; the patient doesn’t have enough healthy blood cells, so the therapy consists of an injection of the patient’s own blood cells which have been gene-edited to be healthy.

Critically, the gene editing of the red blood cells can be done in the lab; trying to devise an injectable or oral substance that would actually transport the gene-editing machinery to an arbitrary part of the body is much harder. (If the trait you’re hoping to affect is cognitive or behavioral, then there’s a good chance the genes that predict it are active in the brain, which is even harder to reach with drugs because of the blood-brain barrier.)

If you look at the list of 37 approved gene and cell therapies to date,

In other words, almost all of these are “easy mode” — genes are either edited outside the body, in the bloodstream, or in unusually accessible places (wound surfaces, muscles, the retina).

We also don’t yet have so-called “multiplex” gene therapies that edit multiple genes at once. Not a single approved gene therapy targets more than one gene; and a typical polygenic score estimates that tens of thousands of genes have significant (though individually tiny) effects on the trait in question.

Finally, every known method of gene editing causes off-target effects — it alters parts of the genetic sequence other than the intended one. The more edits you hope to do, the more cumulative off-target effects you should expect; and thus, the higher the risk of side effects. Even if you could edit hundreds or thousands more genes at once than ever before, it might not be a good idea.

So if you’re not going to use polygenic scores for gene editing, what can you do to produce a high-scoring individual?

Embryo Selection

“Produce multiple embryos via IVF, compute their polygenic scores, and only select the highest-scoring ones to implant” is feasible with today’s technology, and indeed it’s being sold commercially already. Services like Orchid will allow you to screen your IVF embryos for things like cancer risk and select the low-risk ones for implantation.

While this should work for reducing the risk of disease (and miscarriage!) it’s less useful for anything resembling “superbabies”.

Why? Well, a typical cycle of IVF will produce about 5 embryos, and you can choose the best one to implant.

If you’re just trying to dodge diseases, you pick the one with the lowest genetic risk score and that’s a win. Almost definitionally, your child’s disease risk will be lower than if you hadn’t done the test and had instead implanted an embryo at random.

But if you want a child who’s one-in-a-million exceptional, then probably none of your 5 embryos are going to have a polygenic score that extreme. Simple embryo selection isn’t powerful enough to make your baby “super”.

“Iterated Embryo Selection”?

In 2013, Carl Shulman and Nick Bostrom proposed that “iterated embryo selection” could be used for human cognitive enhancement, to produce individuals with extremely high IQ.

The procedure goes:

    select embryos that have high polygenic scores

    extract embryonic stem cells from those embryos and convert them to eggs and sperm

    cross the eggs and sperm to make new embryos

    repeat until large genetic changes have accumulated.

The idea is that you get to “reshuffle” the genes in your set of embryos as many times as you want.

It’s the same process as selective breeding — start with a diverse population and breed the most “successful” offspring to each other. If you look at the difference between wild and domesticated plants and animals, it’s clear this can produce quite dramatic changes!

And of course selective breeding is safer, and less likely to introduce unknown side effects, than massively multiplexed gene editing.

But unlike traditional selective breeding, you don’t have to wait for the organisms to grow up before you know if they’re “successful” — you can select based on genetics alone.

The downside is that each “generation” still might have a very slow turnaround — it takes 6 months for eggs to mature in vivo and it might be similarly time-consuming to generate eggs or sperm from stem cells in the lab.

Moreover, it’s not trivial to “just” turn an embryonic stem cell into an egg or sperm in the lab. That’s known as in vitro gametogenesis and though it’s an active area of research, we’re not quite there yet.

Iterated Meiosis?

There may be an easier way (as developmental biologist Metacelsus pointed out in 2022): meiosis.

His procedure is:

    take a diploid4 cell line

    induce meiosis and generate many haploid cell lines

    genotype the cell lines and select the best ones

    fuse two haploid cells together to re-generate a diploid cell line

    repeat as desired.

Meiosis is the process by which a diploid cell, with two copies of every chromosome, turns into four haploid cells each with a single copy of every chromosome.

Which “half” do the daughter cells get? Well, every instance of meiosis shuffles up the genome roughly randomly, determining which daughter cell will get which genes.

The meiosis-only method skips the challenges of differentiating a stem cell into a gamete, or growing two gametes into a whole embryo. It’s also fastermeiosis only takes a few hours.

The hard part, as he points out, is inducing meiosis to begin with; back in 2022 nobody knew how to turn a “normal” diploid somatic cell into a bunch of haploid cells.

Recently, he solved this problem! Here’s the preprint.

It’s a pretty interesting experimental process; basically it involved an iterative search process for the right set of gene regulatory factors and cell culture conditions to nudge cells into the meiotic state.

This might generalize as a way of discovering how to transform almost any cell in vitro into a desired cell fate or state (assuming it’s possible at all.) How do you differentiate a stem cell into some particular kind of cell type? This sort of iterative, systematic “look for gene expression markers of the desired outcome, then see what combinations of transcription factors make cells express em” process seems like it could be very powerful.

Anyhow, induced meiosis in vitro! We have it now.

That means we can now do iterated meiosis.

At the end of the iterated meiosis process, what you have is a haploid egg-like cell with an “ideal” genetic profile (according to your chosen polygenic score, which by stipulation you trust.)

You’ll still have to fuse that haploid sort-of-egg with another haploid cell to get a diploid cell, for the final round.

And then you’ll have to turn that diploid cell into a viable embryo…which is itself nontrivial.

Generating Naive Pluripotent Cells

You can’t turn a random cell in your body into a viable embryo, even though a skin cell is diploid just like a zygote.

A skin cell is differentiated; it only makes stem cells. By contrast, a zygote is fully pluripotent; it needs to be able to divide and have its descendants grow into every cell in the embryo’s body.

Now, it’s been known for a while that you can differentiate a typical somatic cell (like a skin cell) into a pluripotent stem cell that can differentiate into different tissues. That’s what an induced pluripotent stem cell (iPSC) is!

The so-called Yamanaka factors, discovered by Shinya Yamanaka (who won the Nobel Prize for them) are four transcription factors; when you culture cells with them, they turn into pluripotent stem cells. And iPSCs can differentiate into virtually any kind of cell — nerve, bone, muscle, skin, blood, lung, kidney, you name it.

But can you grow an embryo from an iPSC? A viable one?

Until very recently the answer was “only in certain strains of mice.”

You could get live mouse pups from a stem cell created by growing a somatic mouse cell line with Yamanaka factors; but if you tried that with human cell lines you were out of luck.

In particular, ordinary pluripotent stem cells (whether induced or embryonic) typically can’t contribute to the germline — the cell lineage that ultimately gives rise to eggs and sperm. You can’t “grow” a whole organism without germline cells.

You need naive pluripotent stem cells to grow an embryo, and until last year nobody knew how to create them in vitro in any animal except that particular mouse strain.

In December 2023, Sergiy Velychko (postdoc at the Church Lab at Harvard) found that a variant of one of the Yamanaka factors, dubbed SuperSOX, could transform cell lines into naive pluripotent stem cells, whether they were human, pig, cow, monkey, or mouse. These cells were even able to produce live mouse pups in one of the mouse lines where iPSCs normally can’t produce viable embryos.

“Turn somatic cells into any kind of cell you want” is an incredibly powerful technology for tons of applications. you can suddenly do things like:

Also, if you combine it with induced meiosis, you can do new reproductive tech stuff.

You can take somatic cells from two (genetic) males or females, induce meiosis on them, fuse them together, and then turn that cell into a naive induced pluripotent stem cell and grow it into an embryo. In other words, gay couples could have children that are biologically “both of theirs.”

And, as previously mentioned, you can use iterative meiosis to create an “ideal” haploid cell, fuse it with another haploid cell, and then “superSOX” the result to get an embryo with a desired, extreme polygenic score.

What’s Missing?

Well, one thing we still don’t know how to do in vitro is sex-specific imprinting, the epigenetic phenomenon that causes some genes to be expressed or not depending on whether you got them from your mother or father.

This is relevant because, if you’re producing an embryo from the fusion of two haploid cells, for the genes from one of the parent cells to behave like they’re “from the mother” while the genes from the other behave like they’re “from the father” — even though both “parents” are just normal somatic cells that you’ve turned haploid, not an actual egg and sperm.

This isn’t trivial; when genomic imprinting goes wrong we get fairly serious developmental disabilities like Angelman Syndrome.

Also, we don’t know how to make a “supersperm” (or haploid cell with a Y-chromosome, to be more accurate) from iterated meiosis

That’s the main “known unknown” that I’m aware of; but of course we should expect there to be unknown-unknowns.

Is your synthetic “meiosis” really enough like the real thing, and is the Super-SOX-induced “naive pluripotency” really enough like the real thing, that you get a healthy viable embryo out of this procedure? We’ll need animal experiments, ideally in more than one species, before we can trust that this works as advertised. Ideally you’d follow a large mammal like a monkey, and wait a while — like a year or more — to see if the apparently “healthy” babies produced this way are messed up in any subtle ways.

In general, no, this isn’t ready to make you a designer baby just yet.

And I haven’t even touched on the question of how reliable polygenic scores are, and particularly how likely it is for an embryo optimized for an extremely high polygenic score to actually result in an extreme level of the desired trait.5

But it’s two big pieces of the puzzle (inducing meiosis and inducing naive pluripotency) that didn’t exist until quite recently.

Exciting times!

1

and my own ethical view is that nobody’s civil rights should be in any way violated on account of their genetic code, and that reasonable precautions should be taken to make sure novel human reproductive tech is safe.

2

especially for controversial traits like IQ.

3

it’s famously illegal to “CRISPR” a baby.

4

most cells in the human body are “diploid”, having 2 copies of every chromosome; only eggs and sperm are “haploid”, having 1 copy of every chromosome.

5

“correlation is not causation” becomes relevant here; if too much of the polygenic score is picking up on non-causal correlates of the trait, then selecting an embryo to have an ultra-high score will be optimizing the wrong stuff and won’t help much.

Also, if you’re selecting an embryo to have an even higher polygenic score than anyone in the training dataset, it’s not clear the model will continue to be predictive. It’s probably not possible to get a healthy 10-foot-tall human, no matter how high you push the height polygenic score. And it’s not even clear what it would mean to be a 300-IQ human (though I’d be thrilled to meet one and find out.)



Discuss

Fish AI Reader

Fish AI Reader

AI辅助创作,多种专业模板,深度分析,高质量内容生成。从观点提取到深度思考,FishAI为您提供全方位的创作支持。新版本引入自定义参数,让您的创作更加个性化和精准。

FishAI

FishAI

鱼阅,AI 时代的下一个智能信息助手,助你摆脱信息焦虑

联系邮箱 441953276@qq.com

相关标签

基因筛选 设计婴儿 迭代胚胎选择 多基因评分 基因编辑
相关文章